ImmBioVax

ImmBios portfolio addresses major unmet healthcare needs. ImmBio's lead programme is a vaccine against invasive pneumococcal disease, PnuBioVax, that has recently progressed into full clinical development with the successful completion of a Phase I Clinical trial. Located at the Babraham Institute, on the outskirts of Cambridge, ImmBio was founded... based on advances in understanding of the immune system, in particular the key role of the dendritic cell (DC) in the integration of innate and acquired immunity. ImmBio utilises two distinct technology platforms, ImmBioVax and ImmunoBodies to target antigens to DCs. The lead platform, ImmBioVax, is designed for bacerial vaccines and mimics normal immune responses to a pathogen utilising multi-protein complexes to elicit priming of the immune system. ImmBios unique technologies have the following benefits: ImmBios patent estate covers the products and processes associated with its technologies. The companys lead ImmBioVax programme, PnuBioVax, targets invasive pneumococcal disease. We currently have collaborations with many leading research centres, including the co-development of ImmBio's tuberculosis vaccine, T-BioVax, with a leading Chinese vaccine organisation, the China National Biotech Group.Read More